Selected research
Market Structure
Global Treatments for Alpha-1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Treatments for Alpha-1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Treatments for Alpha-1 include Takeda, Teva Pharmaceutical Industries, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, ProMetic Life Sciences and Kedrion Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Treatments for Alpha-1 market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Treatments for Alpha-1 and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Treatments for Alpha-1 revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Treatments for Alpha-1 market size, projected growth trends, production technologies, key applications, and end-use industries.
Treatments for Alpha-1 Segment by Company
Takeda
Teva Pharmaceutical Industries
Pfizer
GlaxoSmithKline
Baxter
AstraZeneca
Vertex Pharmaceuticals
ProMetic Life Sciences
Kedrion Group
Kamada Ltd
Grifols
CSL Behring
Chiesi Pharmaceuticals
Boehringer Ingelheim
Treatments for Alpha-1 Segment by Type
Augmentation Therapy
Diabetes
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Treatments for Alpha-1 Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Treatments for Alpha-1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatments for Alpha-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Treatments for Alpha-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatments for Alpha-1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Treatments for Alpha-1 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Treatments for Alpha-1 industry.
Chapter 3: Detailed analysis of Treatments for Alpha-1 companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Treatments for Alpha-1revenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Augmentation Therapy
- Diabetes
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Other
Applications
- Hospitals
- Specialty Clinics
- Pharmacies
Companies covered
- Takeda
- Teva Pharmaceutical Industries
- Pfizer
- GlaxoSmithKline
- Baxter
- AstraZeneca
- Vertex Pharmaceuticals
- ProMetic Life Sciences
- Kedrion Group
- Kamada Ltd
- Grifols
- CSL Behring
- Chiesi Pharmaceuticals
- Boehringer Ingelheim
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Treatments for Alpha-1 Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Augmentation Therapy
- 1.2.3 Diabetes
- 1.2.4 Cystic Fibrosis(CF)
- 1.2.5 Non-CF Bronchiectasis(NCFB)
- 1.2.6 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Treatments for Alpha-1 Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospitals
- 1.3.3 Specialty Clinics
- 1.3.4 Pharmacies
- 1.4 Global Market Growth Prospects
- 1.5 Global Treatments for Alpha-1 Growth Trends by Region
- 1.5.1 Global Treatments for Alpha-1 Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Treatments for Alpha-1 Market Size by Region (2021-2026)
- 1.5.3 Treatments for Alpha-1 Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Treatments for Alpha-1 Market Dynamics
- 2.1 Treatments for Alpha-1 Industry Trends
- 2.2 Treatments for Alpha-1 Industry Drivers
- 2.3 Treatments for Alpha-1 Industry Opportunities and Challenges
- 2.4 Treatments for Alpha-1 Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Treatments for Alpha-1 Revenue by Company (2021-2026)
- 3.2 Global Treatments for Alpha-1 Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Treatments for Alpha-1 Key Company Head office and Area Served
- 3.4 Global Treatments for Alpha-1 Company, Product Type & Application
- 3.5 Global Treatments for Alpha-1 Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Treatments for Alpha-1 Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Treatments for Alpha-1 Players Market Share by Revenue in 2025
- 3.6.3 2025 Treatments for Alpha-1 Tier 1, Tier 2, and Tier 3
4 Treatments for Alpha-1 Market by Type
- 4.1 Global Treatments for Alpha-1 Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Treatments for Alpha-1 Market Size by Type (2021-2032)
- 4.3 Global Treatments for Alpha-1 Market Size Share by Type (2021-2032)
5 Treatments for Alpha-1 Market by Application
- 5.1 Global Treatments for Alpha-1 Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Treatments for Alpha-1 Market Size by Application (2021-2032)
- 5.3 Global Treatments for Alpha-1 Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Takeda
- 6.1.1 Takeda Company Information
- 6.1.2 Takeda Business Overview
- 6.1.3 Takeda Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Takeda Treatments for Alpha-1 Product Portfolio
- 6.1.5 Takeda Recent Developments
- 6.2 Teva Pharmaceutical Industries
- 6.2.1 Teva Pharmaceutical Industries Company Information
- 6.2.2 Teva Pharmaceutical Industries Business Overview
- 6.2.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio
- 6.2.5 Teva Pharmaceutical Industries Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Pfizer Treatments for Alpha-1 Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 GlaxoSmithKline
- 6.4.1 GlaxoSmithKline Company Information
- 6.4.2 GlaxoSmithKline Business Overview
- 6.4.3 GlaxoSmithKline Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 GlaxoSmithKline Treatments for Alpha-1 Product Portfolio
- 6.4.5 GlaxoSmithKline Recent Developments
- 6.5 Baxter
- 6.5.1 Baxter Company Information
- 6.5.2 Baxter Business Overview
- 6.5.3 Baxter Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Baxter Treatments for Alpha-1 Product Portfolio
- 6.5.5 Baxter Recent Developments
- 6.6 AstraZeneca
- 6.6.1 AstraZeneca Company Information
- 6.6.2 AstraZeneca Business Overview
- 6.6.3 AstraZeneca Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 AstraZeneca Treatments for Alpha-1 Product Portfolio
- 6.6.5 AstraZeneca Recent Developments
- 6.7 Vertex Pharmaceuticals
- 6.7.1 Vertex Pharmaceuticals Company Information
- 6.7.2 Vertex Pharmaceuticals Business Overview
- 6.7.3 Vertex Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio
- 6.7.5 Vertex Pharmaceuticals Recent Developments
- 6.8 ProMetic Life Sciences
- 6.8.1 ProMetic Life Sciences Company Information
- 6.8.2 ProMetic Life Sciences Business Overview
- 6.8.3 ProMetic Life Sciences Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio
- 6.8.5 ProMetic Life Sciences Recent Developments
- 6.9 Kedrion Group
- 6.9.1 Kedrion Group Company Information
- 6.9.2 Kedrion Group Business Overview
- 6.9.3 Kedrion Group Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Kedrion Group Treatments for Alpha-1 Product Portfolio
- 6.9.5 Kedrion Group Recent Developments
- 6.10 Kamada Ltd
- 6.10.1 Kamada Ltd Company Information
- 6.10.2 Kamada Ltd Business Overview
- 6.10.3 Kamada Ltd Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Kamada Ltd Treatments for Alpha-1 Product Portfolio
- 6.10.5 Kamada Ltd Recent Developments
- 6.11 Grifols
- 6.11.1 Grifols Company Information
- 6.11.2 Grifols Business Overview
- 6.11.3 Grifols Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Grifols Treatments for Alpha-1 Product Portfolio
- 6.11.5 Grifols Recent Developments
- 6.12 CSL Behring
- 6.12.1 CSL Behring Company Information
- 6.12.2 CSL Behring Business Overview
- 6.12.3 CSL Behring Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 CSL Behring Treatments for Alpha-1 Product Portfolio
- 6.12.5 CSL Behring Recent Developments
- 6.13 Chiesi Pharmaceuticals
- 6.13.1 Chiesi Pharmaceuticals Company Information
- 6.13.2 Chiesi Pharmaceuticals Business Overview
- 6.13.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio
- 6.13.5 Chiesi Pharmaceuticals Recent Developments
- 6.14 Boehringer Ingelheim
- 6.14.1 Boehringer Ingelheim Company Information
- 6.14.2 Boehringer Ingelheim Business Overview
- 6.14.3 Boehringer Ingelheim Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio
- 6.14.5 Boehringer Ingelheim Recent Developments
7 North America
- 7.1 North America Treatments for Alpha-1 Market Size (2021-2032)
- 7.2 North America Treatments for Alpha-1 Market Size by Type
- 7.2.1 North America Treatments for Alpha-1 Market Size by Type (2021-2026)
- 7.2.2 North America Treatments for Alpha-1 Market Size by Type (2027-2032)
- 7.2.3 North America Treatments for Alpha-1 Market Share by Type (2021-2032)
- 7.3 North America Treatments for Alpha-1 Market Size by Application
- 7.3.1 North America Treatments for Alpha-1 Market Size by Application (2021-2026)
- 7.3.2 North America Treatments for Alpha-1 Market Size by Application (2027-2032)
- 7.3.3 North America Treatments for Alpha-1 Market Share by Application (2021-2032)
- 7.4 North America Treatments for Alpha-1 Market Size by Country
- 7.4.1 North America Treatments for Alpha-1 Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Treatments for Alpha-1 Market Size by Country (2021-2026)
- 7.4.3 North America Treatments for Alpha-1 Market Size by Country (2027-2032)
- 7.4.4 North America Treatments for Alpha-1 Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Treatments for Alpha-1 Market Size (2021-2032)
- 8.2 Europe Treatments for Alpha-1 Market Size by Type
- 8.2.1 Europe Treatments for Alpha-1 Market Size by Type (2021-2026)
- 8.2.2 Europe Treatments for Alpha-1 Market Size by Type (2027-2032)
- 8.2.3 Europe Treatments for Alpha-1 Market Share by Type (2021-2032)
- 8.3 Europe Treatments for Alpha-1 Market Size by Application
- 8.3.1 Europe Treatments for Alpha-1 Market Size by Application (2021-2026)
- 8.3.2 Europe Treatments for Alpha-1 Market Size by Application (2027-2032)
- 8.3.3 Europe Treatments for Alpha-1 Market Share by Application (2021-2032)
- 8.4 Europe Treatments for Alpha-1 Market Size by Country
- 8.4.1 Europe Treatments for Alpha-1 Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Treatments for Alpha-1 Market Size by Country (2021-2026)
- 8.4.3 Europe Treatments for Alpha-1 Market Size by Country (2027-2032)
- 8.4.4 Europe Treatments for Alpha-1 Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Treatments for Alpha-1 Market Size (2021-2032)
- 9.2 China Treatments for Alpha-1 Market Size by Type
- 9.2.1 China Treatments for Alpha-1 Market Size by Type (2021-2026)
- 9.2.2 China Treatments for Alpha-1 Market Size by Type (2027-2032)
- 9.2.3 China Treatments for Alpha-1 Market Share by Type (2021-2032)
- 9.3 China Treatments for Alpha-1 Market Size by Application
- 9.3.1 China Treatments for Alpha-1 Market Size by Application (2021-2026)
- 9.3.2 China Treatments for Alpha-1 Market Size by Application (2027-2032)
- 9.3.3 China Treatments for Alpha-1 Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Treatments for Alpha-1 Market Size (2021-2032)
- 10.2 Asia Treatments for Alpha-1 Market Size by Type
- 10.2.1 Asia Treatments for Alpha-1 Market Size by Type (2021-2026)
- 10.2.2 Asia Treatments for Alpha-1 Market Size by Type (2027-2032)
- 10.2.3 Asia Treatments for Alpha-1 Market Share by Type (2021-2032)
- 10.3 Asia Treatments for Alpha-1 Market Size by Application
- 10.3.1 Asia Treatments for Alpha-1 Market Size by Application (2021-2026)
- 10.3.2 Asia Treatments for Alpha-1 Market Size by Application (2027-2032)
- 10.3.3 Asia Treatments for Alpha-1 Market Share by Application (2021-2032)
- 10.4 Asia Treatments for Alpha-1 Market Size by Country
- 10.4.1 Asia Treatments for Alpha-1 Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Treatments for Alpha-1 Market Size by Country (2021-2026)
- 10.4.3 Asia Treatments for Alpha-1 Market Size by Country (2027-2032)
- 10.4.4 Asia Treatments for Alpha-1 Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Treatments for Alpha-1 Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Type
- 11.2.1 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Treatments for Alpha-1 Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Application
- 11.3.1 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Treatments for Alpha-1 Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Country
- 11.4.1 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Treatments for Alpha-1 Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Treatments for Alpha-1 Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst